Stefania Scala

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2166786/publications.pdf

Version: 2024-02-01

119 papers	5,603 citations	66343 42 h-index	88630 70 g-index
121 all docs	121 docs citations	121 times ranked	8814 citing authors

#	Article	IF	Citations
1	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochemical Pharmacology, 2010, 79, 817-824.	4.4	312
2	Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. Clinical Cancer Research, 2005, 11, 1835-1841.	7.0	260
3	P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups. Molecular Pharmacology, 1997, 51, 1024-1033.	2.3	228
4	Molecular Pathways: Targeting the CXCR4â€“CXCL12 Axisâ€”Untapped Potential in the Tumor Microenvironment. Clinical Cancer Research, 2015, 21, 4278-4285.	7.0	221
5	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. Journal of Clinical Oncology, 2005, 23, 7660-7668.	1.6	218
6	Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients. Clinical Cancer Research, 2006, 12, 2795-2803.	7.0	158
7	Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4256-4261.	7.1	146
8	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clinical Immunology, 2010, 134, 237-250.	3.2	131
9	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 2020, 60, 351-361.	9.6	122
10	Human Melanoma Metastases Express Functional CXCR4. Clinical Cancer Research, 2006, 12, 2427-2433.	7.0	114
11	Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene, 1998, 17, 413-418.	5.9	113
12	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. Cancer Treatment Reviews, 2016, 48, 61-68.	7.7	102
13	Cystic Fibrosis Transmembrane Conductance Regulator and Adenosine Triphosphate. Science, 1997, 275, 1324-1326.	12.6	99
14	Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. Journal of Experimental and Clinical Cancer Research, 2016, 35, 55.	8.6	89
15	Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. Journal of Cellular Biochemistry, 1997, 65, 513-526.	2.6	87
16	Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer. Scientific Reports, 2015, 5, 10357.	3.3	87
17	Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation. Molecular and Cellular Biology, 2001, 21, 2485-2495.	2.3	86
18	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine, 2017, 15, 46.	4.4	85

#	Article	IF	Citations
19	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunology, Immunotherapy, 2005, 54, 781-791.	4.2	78
20	Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment . Cancer Management and Research, 2019, Volume 11, 3847-3860.	1.9	78
21	Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle, 2010, 9, 4492-4500.	2.6	77
22	Detection, monitoring, and management of trastuzumabâ€induced left ventricular dysfunction: an actual challenge. European Journal of Heart Failure, 2012, 14, 130-137.	7.1	77
23	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. PLoS ONE, 2013, 8, e74548.	2.5	76
24	A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. Cancer Letters, 2016, 370, 100-107.	7.2	74
25	Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. Journal of Experimental and Clinical Cancer Research, 2019, 38, 432.	8.6	74
26	Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer. Current Cancer Drug Targets, 2010, 10, 772-781.	1.6	73
27	Prostate Cancer Detection in the â€œGrey Areaâ€•of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chunâ€™s Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3. European Urology, 2011, 59, 81-87.	1.9	73
28	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU International, 2013, 112, 686-696.	2.5	70
29	CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death and Disease, 2014, 5, e1310-e1310.	6.3	70
30	Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl922-947. Clinical Cancer Research, 2008, 14, 6505-6514.	7.0	64
31	Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. Cancer Immunology Research, 2016, 4, 366-374.	3.4	61
32	Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer, 2016, 16, 918.	2.6	60
33	Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy. Oncology, 2016, 90, 36-42.	1.9	60
34	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget, 2017, 8, 77110-77120.	1.8	59
35	Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunology, Immunotherapy, 2012, 61, 1713-1720.	4.2	55
36	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget, 2015, 6, 8261-8270.	1.8	54

#	Article	IF	Citations
37	Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene, 1998, 17, 377-385.	5.9	51
38	ONYX-015, an E1B Gene-Defective Adenovirus, Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2525-2531.	3.6	50
39	Ionizing radiation effects on the tumor microenvironment. Seminars in Oncology, 2019, 46, 254-260.	2.2	50
40	CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 591386.	2.8	49
41	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. Neoplasia, 2012, 14, 1223-IN43.	5.3	48
42	Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. Journal of Experimental and Clinical Cancer Research, 2017, 36, 104.	8.6	47
43	Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach. Oncotarget, 2017, 8, 41890-41902.	1.8	47
44	Serum cytokine levels in patients with hepatocellular carcinoma. European Cytokine Network, 2010, 21, 99-104.	2.0	45
45	CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cellular and Molecular Immunology, 2015, 12, 474-482.	10.5	39
46	Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.. Journal of Clinical Investigation, 1995, 96, 1026-1034.	8.2	38
47	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 22.	8.6	37
48	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunology, Immunotherapy, 2007, 56, 1589-1595.	4.2	36
49	CXCR4â€“CXCL12â€“CXCR7, TLR2â€“TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. OncoImmunology, 2016, 5, e1254313.	4.6	36
50	Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. Journal of Translational Medicine, 2012, 10, 232.	4.4	34
51	CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. European Journal of Cardio-thoracic Surgery, 2012, 41, 368-375.	1.4	33
52	Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. Immunotherapy, 2020, 12, 105-110.	2.0	33
53	A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. International Journal of Cancer, 2014, 135, 379-390.	5.1	32
54	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. International Journal of Molecular Sciences, 2016, 17, 790.	4.1	32

#	Article	IF	Citations
55	Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biology and Therapy, 2010, 9, 423-429.	3.4	30
56	Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemotherapy and Pharmacology, 1997, 40, 245-250.	2.3	28
57	High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer. Current Cancer Drug Targets, 2012, 12, 693-702.	1.6	28
58	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers, 2020, 12, 3073.	3.7	28
59	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. Journal of Leukocyte Biology, 2021, 109, 969-989.	3.3	28
60	Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Research, 2004, 24, 4255-8.	1.1	28
61	Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. Journal of Translational Medicine, 2010, 8, 109.	4.4	27
62	CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Frontiers in Bioscience - Elite, 2010, E2, 13-21.	1.8	27
63	Inhibition of Sp1 activity by a decoy PNAâ€“DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochemical Pharmacology, 2005, 70, 1277-1287.	4.4	26
64	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget, 2016, 7, 18865-18875.	1.8	26
65	Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. Journal of Medicinal Chemistry, 2016, 59, 8369-8380.	6.4	26
66	CXCL12 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1302, 51-70.	1.6	26
67	Study of Ras Mutationsâ€™ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Cancers, 2020, 12, 1919.	3.7	25
68	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. , 2022, 10, e004032.		25
69	Soluble interleukin-2 receptor in stage Iâ€“III melanoma. Cytokine, 2006, 33, 150-155.	3.2	24
70	Prognostic role of the <scp>CDNK</scp>1B V109G polymorphism in multiple endocrine neoplasia type 1. Journal of Cellular and Molecular Medicine, 2015, 19, 1735-1741.	3.6	23
71	Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)â€“Ligand Interactions on Living Cancer Cells. Journal of Medicinal Chemistry, 2018, 61, 2910-2923.	6.4	22
72	A possible predictive marker of progression for hepatocellular carcinoma. Oncology Letters, 2011, 2, 1247-1251.	1.8	21

#	Article	IF	Citations
73	Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biology, 2016, 6, 160254.	3.6	21
74	Structureâ€“Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist. Journal of Medicinal Chemistry, 2017, 60, 9641-9652.	6.4	21
75	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. Cell Death and Disease, 2020, 11, 275.	6.3	21
76	Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110114.	3.2	21
77	CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells. Frontiers in Immunology, 2020, 11, 02168.	4.8	20
78	Cellular and Biophysical Evidence for Interactions between Adenosine Triphosphate and P-Glycoprotein Substrates: Functional Implications for Adenosine Triphosphate/Drug Cotransport in P-Glycoprotein Overexpressing Tumor Cells and in P-Glycoprotein Low-Level Expressing Erythrocytes. Blood Cells, Molecules, and Diseases, 2001, 27, 181-200.	1.4	18
79	Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it. International Journal of Surgery, 2015, 21, S89-S94.	2.7	17
80	A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors. Scientific Reports, 2017, 7, 2554.	3.3	17
81	Coexpression of TGF??, Epidermal Growth Factor Receptor, and P-Glycoprotein in Normal and Benign Diseased Breast Tissues. Diagnostic Molecular Pathology, 1995, 4, 136-142.	2.1	16
82	Interaction between HMGA1 and Retinoblastoma Protein Is Required for Adipocyte Differentiation. Journal of Biological Chemistry, 2009, 284, 25993-26004.	3.4	16
83	New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer. Cancers, 2020, 12, 1952.	3.7	16
84	Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biology and Therapy, 2013, 14, 175-183.	3.4	15
85	CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Nanoscale, 2016, 8, 7562-7571.	5.6	15
86	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. Frontiers in Immunology, 2020, 11, 1201.	4.8	15
87	The Nâ€terminal Region of CXCL11 as Structural Template for CXCR3 Molecular Recognition: Synthesis, Conformational Analysis, and Binding Studies. Chemical Biology and Drug Design, 2012, 80, 254-265.	3.2	14
88	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunology, Immunotherapy, 2005, 54, 44-50.	4.2	12
89	Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 755-760.	1.2	12
90	HMGI-C gene expression is not required for in vivo thyroid cell transformation. Carcinogenesis, 2001, 22, 251-256.	2.8	11

#	Article	IF	Citations
91	A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. Cell Cycle, 2009, 8, 1228-1237.	2.6	11
92	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. Journal of Experimental and Clinical Cancer Research, 2018, 37, 297.	8.6	11
93	Temozolomide and cisplatin in avdanced malignant melanoma. Anticancer Research, 2005, 25, 1441-7.	1.1	11
94	Adjuvant treatment of malignant melanoma: Where are we?. Critical Reviews in Oncology/Hematology, 2006, 57, 45-52.	4.4	10
95	Cationic nucleopeptides as novel non-covalent carriers for the delivery of peptide nucleic acid (PNA) and RNA oligomers. Bioorganic and Medicinal Chemistry, 2018, 26, 2539-2550.	3.0	10
96	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. BMC Cancer, 2019, 19, 899.	2.6	10
97	Disulfide Bond Replacement with 1,4â€•and 1,5â€Disubstituted [1,2,3]â€Triazole on Câ€Xâ€C Chemokine Receptor Type 4 (CXCR4) Peptide Ligands: Small Changes that Make Big Differences. Chemistry - A European Journal, 2020, 26, 10113-10125.	3.3	10
98	Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximatedgenetic subtypes. Journal of Radiation Research, 2013, 54, 292-298.	1.6	9
99	Engineering of thermoresponsive gels as a fake metastatic niche. Carbohydrate Polymers, 2018, 191, 112-118.	10.2	9
100	CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells. Cell Death and Disease, 2019, 10, 562.	6.3	9
101	New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. Vaccines, 2020, 8, 164.	4.4	9
102	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. Molecular Therapy, 2021, 29, 2963-2978.	8.2	9
103	Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies. Journal of Peptide Science, 2014, 20, 270-278.	1.4	8
104	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	6.4	8
105	Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal. Cancers, 2021, 13, 3284.	3.7	8
106	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. Cancers, 2021, 13, 4236.	3.7	8
107	Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy. World Journal of Clinical Cases, 2017, 5, 390.	0.8	8
108	Cetuximab-dependent ADCC in cancer: dream or reality?. Cancer Immunology, Immunotherapy, 2010, 59, 1607-1608.	4.2	7

#	Article	IF	Citations
109	Conformational Ensembles Explored Dynamically from Disordered Peptides Targeting Chemokine Receptor CXCR4. International Journal of Molecular Sciences, 2015, 16, 12159-12173.	4.1	7
110	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198922.	3.2	7
111	Intrinsically disordered amphiphilic peptides as potential targets in drug delivery vehicles. Molecular BioSystems, 2015, 11, 2925-2932.	2.9	6
112	Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter. Human Immunology, 1995, 42, 245-253.	2.4	5
113	Predictive immune biomarkers: an unattainable chimera?. Cellular and Molecular Immunology, 2018, 15, 740-742.	10.5	5
114	Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers, 2020, 12, 2422.	3.7	5
115	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients. Cancers, 2022, 14, 1849.	3.7	3
116	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori, 2013, 99, 293e-8e.	1.1	3
117	CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages Iâ€“III melanoma patients. Cancer Immunology, Immunotherapy, 2010, 59, 511-517.	4.2	1
118	Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition. Frontiers in Immunology, 2013, 3, 409.	4.8	0
119	Tissue Micro Arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 1814-8.	0.5	0